Infliximab for the treatment of pediatric ulcerative colitis

References

• Hyams JS. Inflammatory bowel disease. Pediatr. Rev. 26(9), 314–320 (2005).
   PubMed Web of Science ®Google Scholar
• Cuffari C. Inflammatory bowel disease in children: a pediatrician’s perspective. Minerva Pediatr. 58(2), 139–157 (2006).
   PubMedGoogle Scholar
• Waterman M, Xu W, Stempak JM et al. Distinct and overlapping genetic loci in Crohn’s disease and ulcerative colitis: correlations with pathogenesis. Inflamm. Bowel Dis. 17(9), 1936–1942 (2011).
   PubMed Web of Science ®Google Scholar
• Gearry RB, Richardson AK, Frampton CM, Dodgshun AJ, Barclay ML. Population-based cases control study of inflammatory bowel disease risk factors. J. Gastroenterol. Hepatol. 25(2), 325–333 (2010).
   PubMed Web of Science ®Google Scholar
• Sawczenko A, Sandhu BK. Presenting features of inflammatory bowel disease in Great Britain and Ireland. Arch. Dis. Child. 88(11), 995–1000 (2003).
   PubMed Web of Science ®Google Scholar
• Uchida K, Araki T, Toiyama Y et al. Preoperative steroid-related complications in Japanese pediatric patients with ulcerative colitis. Dis. Colon Rectum 49(1), 74–79 (2006).
   PubMed Web of Science ®Google Scholar
• Carvalho R, Hyams JS. Diagnosis and management of inflammatory bowel disease in children. Semin. Pediatr. Surg. 16(3), 164–171 (2007).
   PubMedGoogle Scholar
• Rajaratnam SG, Eglinton TW, Hider P, Fearnhead NS. Impact of ileal pouch–anal anastomosis on female fertility: meta-analysis and systematic review. Int. J. Colorectal Dis. 26(11), 1365–1374 (2011).
   PubMed Web of Science ®Google Scholar
• Greifer MK, Markowitz JF. Update in the treatment of paediatric ulcerative colitis. Expert Opin. Pharmacother. 7(14), 1907–1918 (2006).
   PubMed Web of Science ®Google Scholar
• Devlin SM, Panaccione R. Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up. Gastroenterol. Clin. North Am. 38(4), 577–594 (2009).
   PubMed Web of Science ®Google Scholar
• Dagata ID, Vanounou T, Seidman E. Mesalamine in pediatric inflammatory bowel disease: a 10-year experience. Inflamm. Bowel Dis. 2(4), 229–235 (1996).
   PubMed Web of Science ®Google Scholar
• Hyams J, Markowitz J, Lerer T et al.; Pediatric Inflammatory Bowel Disease Collaborative Research Group. The natural history of corticosteroid therapy for ulcerative colitis in children. Clin. Gastroenterol. Hepatol. 4(9), 1118–1123 (2006).
   PubMed Web of Science ®Google Scholar
• Hyams JS, Lerer T, Mack D et al.; Pediatric Inflammatory Bowel Disease Collaborative Research Group Registry. Outcome following thiopurine use in children with ulcerative colitis: a prospective multicenter registry study. Am. J. Gastroenterol. 106(5), 981–987 (2011).
   PubMed Web of Science ®Google Scholar
• Castro M, Papadatou B, Ceriati E et al. Role of cyclosporin in preventing or delaying colectomy in children with severe ulcerative colitis. Langenbecks Arch. Surg. 392(2), 161–164 (2007).
   PubMed Web of Science ®Google Scholar
• Hyams J, Damaraju L, Blank M et al.; T72 Study Group. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. Clin. Gastroenterol. Hepatol. 10(4), 391–399.e1 (2012).
   PubMed Web of Science ®Google Scholar
• Khan KJ, Ullman TA, Ford AC et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am. J. Gastroenterol. 106(4), 661–673 (2011).
   PubMed Web of Science ®Google Scholar
• Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am. J. Gastroenterol. 104(2), 437–443 (2009).
   PubMed Web of Science ®Google Scholar
• Dubinsky MC. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin. Gastroenterol. Hepatol. 2(9), 731–743 (2004).
   PubMed Web of Science ®Google Scholar
• Bradley GM, Oliva-Hemker M. Pediatric ulcerative colitis: current treatment approaches including role of infliximab. Biologics 6, 125–134 (2012).
   PubMedGoogle Scholar
• Veres G, Baldassano RN, Mamula P. Infliximab therapy in children and adolescents with inflammatory bowel disease. Drugs 67(12), 1703–1723 (2007).
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D. Challenges of predicting treatment response in patients with rheumatoid arthritis. Nat. Clin. Pract. Rheumatol. 1(2), 62–63 (2005).
   PubMedGoogle Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR et al.; ACCENT I Study Group. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359(9317), 1541–1549 (2002).
   PubMed Web of Science ®Google Scholar
• Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N. Engl. J. Med. 350(9), 876–885 (2004).
   PubMed Web of Science ®Google Scholar
• Hyams J, Crandall W, Kugathasan S et al.; REACH Study Group. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology 132(3), 863–873; quiz 1165 (2007).
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353(23), 2462–2476 (2005).
   PubMed Web of Science ®Google Scholar
• Mamula P, Markowitz JE, Brown KA, Hurd LB, Piccoli DA, Baldassano RN. Infliximab as a novel therapy for pediatric ulcerative colitis. J. Pediatr. Gastroenterol. Nutr. 34(3), 307–311 (2002).
   PubMed Web of Science ®Google Scholar
• Mamula P, Markowitz JE, Cohen LJ, von Allmen D, Baldassano RN. Infliximab in pediatric ulcerative colitis: two-year follow-up. J. Pediatr. Gastroenterol. Nutr. 38(3), 298–301 (2004).
   PubMed Web of Science ®Google Scholar
• Russell GH, Katz AJ. Infliximab is effective in acute but not chronic childhood ulcerative colitis. J. Pediatr. Gastroenterol. Nutr. 39(2), 166–170 (2004).
   PubMed Web of Science ®Google Scholar
• Eidelwein AP, Cuffari C, Abadom V, Oliva-Hemker M. Infliximab efficacy in pediatric ulcerative colitis. Inflamm. Bowel Dis. 11(3), 213–218 (2005).
   PubMed Web of Science ®Google Scholar
• Fanjiang G, Russell GH, Katz AJ. Short- and long-term response to and weaning from infliximab therapy in pediatric ulcerative colitis. J. Pediatr. Gastroenterol. Nutr. 44(3), 312–317 (2007).
   PubMed Web of Science ®Google Scholar
• Cucchiara S, Romeo E, Viola F et al. Infliximab for pediatric ulcerative colitis: a retrospective Italian multicenter study. Dig. Liver Dis. 40(Suppl. 2), S260–S264 (2008).
   PubMedGoogle Scholar
• McGinnis JK, Murray KF. Infliximab for ulcerative colitis in children and adolescents. J. Clin. Gastroenterol. 42(8), 875–879 (2008).
   PubMed Web of Science ®Google Scholar
• Hyams JS, Lerer T, Griffiths A et al.; Pediatric Inflammatory Bowel Disease Collaborative Research Group. Outcome following infliximab therapy in children with ulcerative colitis. Am. J. Gastroenterol. 105(6), 1430–1436 (2010).
   PubMed Web of Science ®Google Scholar
• Tiemi J, Komati S, Sdepanian VL. Effectiveness of infliximab in Brazilian children and adolescents with Crohn disease and ulcerative colitis according to clinical manifestations, activity indices of inflammatory bowel disease, and corticosteroid use. J. Pediatr. Gastroenterol. Nutr. 50(6), 628–633 (2010).
   PubMed Web of Science ®Google Scholar
• Breese EJ, Michie CA, Nicholls SW et al. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 106(6), 1455–1466 (1994).
   PubMed Web of Science ®Google Scholar
• Reinecker HC, Steffen M, Witthoeft T et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn’s disease. Clin. Exp. Immunol. 94(1), 174–181 (1993).
   PubMed Web of Science ®Google Scholar
• Cornillie F, Shealy D, D’Haens G et al. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn’s disease. Aliment. Pharmacol. Ther. 15(4), 463–473 (2001).
   PubMed Web of Science ®Google Scholar
• Van den Brande JM, Braat H, van den Brink GR et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s disease. Gastroenterology 124(7), 1774–1785 (2003).
   PubMed Web of Science ®Google Scholar
• Baert FJ, D’Haens GR, Peeters M et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn’s ileocolitis. Gastroenterology 116(1), 22–28 (1999).
   PubMed Web of Science ®Google Scholar
• Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 119(4), 1148–1157 (2000).
   PubMed Web of Science ®Google Scholar
• Danese S, Sans M, Scaldaferri F et al. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn’s disease. J. Immunol. 176(4), 2617–2624 (2006).
   PubMed Web of Science ®Google Scholar
• Fasanmade AA, Adedokun OJ, Ford J et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur. J. Clin. Pharmacol. 65(12), 1211–1228 (2009).
   PubMed Web of Science ®Google Scholar
• Fasanmade AA, Adedokun OJ, Blank M, Zhou H, Davis HM. Pharmacokinetic properties of infliximab in children and adults with Crohn’s disease: a retrospective analysis of data from 2 Phase III clinical trials. Clin. Ther. 33(7), 946–964 (2011).
   PubMed Web of Science ®Google Scholar
• Turner D, Mack D, Leleiko N et al. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology 138(7), 2282–2291 (2010).
   PubMed Web of Science ®Google Scholar
• Turner D, Otley AR, Mack D et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 133(2), 423–432 (2007).
   PubMed Web of Science ®Google Scholar
• Turner D, Hyams J, Markowitz J et al.; Pediatric IBD Collaborative Research Group. Appraisal of the pediatric ulcerative colitis activity index (PUCAI). Inflamm. Bowel Dis. 15(8), 1218–1223 (2009).
   PubMed Web of Science ®Google Scholar
• Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J. Dermatolog. Treat. 20(2), 100–108 (2009).
   PubMed Web of Science ®Google Scholar
• Toussirot E, Houvenagel E, Goeb V et al. Development of inflammatory bowel disease during anti-TNF-alpha therapy for inflammatory rheumatic disease. A nationwide series. Joint Bone Spine doi:10.1016/j.jbspin.2011.10.001 (2011) (Epub ahead of print).
   Google Scholar
• Fromont A, De Seze J, Fleury MC, Maillefert JF, Moreau T. Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. Cytokine 45(2), 55–57 (2009).
   PubMed Web of Science ®Google Scholar
• Jacobstein DA, Markowitz JE, Kirschner BS et al. Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm. Bowel Dis. 11(5), 442–446 (2005).
   PubMed Web of Science ®Google Scholar
• Miele E, Markowitz JE, Mamula P, Baldassano RN. Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J. Pediatr. Gastroenterol. Nutr. 38(5), 502–508 (2004).
   PubMed Web of Science ®Google Scholar
• Lamireau T, Cézard JP, Dabadie A et al.; French-Speaking Group for Pediatric Gastroenterology Nutrition. Efficacy and tolerance of infliximab in children and adolescents with Crohn’s disease. Inflamm. Bowel Dis. 10(6), 745–750 (2004).
   PubMed Web of Science ®Google Scholar
• Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin. Infect. Dis. 38(9), 1261–1265 (2004).
   PubMed Web of Science ®Google Scholar
• Pérez-Alvarez R, Díaz-Lagares C, García-Hernández F et al.; BIOGEAS Study Group. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore) 90(6), 359–371 (2011).
   PubMed Web of Science ®Google Scholar
• Ferkolj I. How to improve the safety of biologic therapy in Crohn’s disease. J. Physiol. Pharmacol. 60(Suppl. 7), 67–70 (2009).
   PubMed Web of Science ®Google Scholar
• Diak P, Siegel J, La Grenade L, Choi L, Lemery S, McMahon A. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum. 62(8), 2517–2524 (2010).
   PubMed Web of Science ®Google Scholar
• Rosh JR, Gross T, Mamula P, Griffiths A, Hyams J. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn’s disease: a cautionary tale? Inflamm. Bowel Dis. 13(8), 1024–1030 (2007).
   PubMed Web of Science ®Google Scholar
• Sprakes MB, Ford AC, Suares NC et al. Costs of care for Crohn’s disease following the introduction of infliximab: a single-centre UK experience. Aliment. Pharmacol. Ther. 32(11–12), 1357–1363 (2010).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, van Assche G, Reinisch W et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 142(2), 257–265.e1 (2012).
   PubMed Web of Science ®Google Scholar
• Hyams JS, Griffiths A, Markowitz J et al. Safety and efficacy of adalimumab for moderate to severe Crohn’s disease in children. Gastroenterology 143(2), 365–374.e2 (2012).
   PubMed Web of Science ®Google Scholar
• Bousvaros A. Use of immunomodulators and biologic therapies in children with inflammatory bowel disease. Expert Rev. Clin. Immunol. 6(4), 659–666 (2010).
   PubMed Web of Science ®Google Scholar
• Alexander F. Complications of ileal pouch anal anastomosis. Semin. Pediatr. Surg. 16(3), 200–204 (2007).
   PubMedGoogle Scholar
• Steenholdt C, Molazahi A, Ainsworth MA, Brynskov J, Østergaard Thomsen O, Seidelin JB. Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study. Scand. J. Gastroenterol. 47(5), 518–527 (2012).
   PubMed Web of Science ®Google Scholar
• Kugathasan S, Levy MB, Saeian K et al. Infliximab retreatment in adults and children with Crohn’s disease: risk factors for the development of delayed severe systemic reaction. Am. J. Gastroenterol. 97(6), 1408–1414 (2002).
   PubMed Web of Science ®Google Scholar
• Domènech E, Zabana Y, Mañosa M, Garcia-Planella E, Cabré E, Gassull MA. Infliximab reintroduction is not associated to a higher rate of immune-related adverse effects in patients with inflammatory bowel disease initially treated with a three-infusion induction regimen. J. Clin. Gastroenterol. 44(1), 34–37 (2010).
   PubMed Web of Science ®Google Scholar
• Lees CW, Barrett JC, Parkes M, Satsangi J. New IBD genetics: common pathways with other diseases. Gut 60(12), 1739–1753 (2011).
   PubMed Web of Science ®Google Scholar